Stay updated on Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial

Sign up to get notified when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2, replacing the previous v3.0.1, and the 'Back to Top' element has been removed.
    Difference
    0.7%
    Check dated 2025-09-13T17:42:05.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.7%
    Check dated 2025-09-06T15:25:50.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries.
    Difference
    20%
    Check dated 2025-08-30T12:12:00.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The date has been updated from August 9, 2024, to August 20, 2025.
    Difference
    0.6%
    Check dated 2025-08-23T08:03:04.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-16T04:45:42.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-09T00:00:56.000Z thumbnail image

Stay in the know with updates to Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.